お知らせ :東京証券取引所JASDAQスタンダード市場への新規上場に関するお知らせ
株式会社グローバルインフォメーション
表紙:がん分子診断 (MDx) の市場予測:2021年~2025年
市場調査レポート
商品コード
999976

がん分子診断 (MDx) の市場予測:2021年~2025年

Molecular Diagnostics for Cancer. Markets Forecasts by Cancer Type, Product and Place with Executive and Consultant Guides and Customization. 2021 to 2025

出版日: | 発行: Howe Sound Research | ページ情報: 英文 413 Pages | 納期: 即日から翌営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=112.06円
がん分子診断 (MDx) の市場予測:2021年~2025年
出版日: 2021年04月09日
発行: Howe Sound Research
ページ情報: 英文 413 Pages
納期: 即日から翌営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

がんの分子診断 (MDx) は、ゲノミクスの知識の急増から直接恩恵を受けるところまで来ています。がんのコンパニオン診断は、業界を再形成する新しい市場セグメントです。

当レポートでは、世界のがん分子診断市場について調査分析し、130社以上を対象に、市場戦略、動向、予測について、体系的な情報を提供しています。

目次

第1章 分子診断 (MDx) 市場:COVIDパンデミックの影響による戦略的状況分析

第2章 エグゼクティブ、マーケティング、販売、ビジネス開発スタッフ向けガイド

第3章 経営コンサルタント・投資顧問向けガイド

第4章 イントロダクションと市場の定義

  • 分子診断とは
  • 診断の革命
  • 市場の定義
  • 調査手法
  • 米国の医療市場と臨床検査 - 見通し

第5章 市場概要

  • 市場参入企業
  • 市場セグメント
  • 業界構造

第6章 市場動向

  • 成長促進要因
  • 成長阻害要因
  • 計装と自動化
  • 診断技術の発展

第7章 分子診断 (MDx) の最近の開発

第8章 分子診断 (MDx) の主要企業プロファイル

  • 10x Genomics, Inc
  • Abbott Diagnostics
  • AccuraGen Inc.
  • Adaptive Biotechnologies
  • Aethlon Medical
  • Agena Bioscience, Inc.
  • Agilent
  • Anchor Dx
  • ANGLE plc
  • ApoCell, Inc.
  • ArcherDx, Inc.
  • ARUP Laboratories
  • Asuragen
  • AVIVA Biosciences
  • Baylor Miraca Genetics Laboratories
  • Beckman Coulter, Inc.
  • BGI Genomics Co. Ltd
  • Bioarray Genetics
  • Biocartis
  • Biocept, Inc
  • Biodesix Inc.
  • BioFluidica
  • BioGenex
  • Biolidics Ltd
  • bioMérieux Diagnostics
  • Bioneer Corporation
  • Bio-Rad Laboratories, Inc
  • Bio-Reference Laboratories
  • Bio-Techne
  • Bioview
  • Bolidics
  • Boreal Genomics
  • Bristol-Myers Squibb
  • Cancer Genetics
  • Caris Molecular Diagnostics
  • CellMax Life
  • Cepheid (now Danaher)
  • Charles River Laboratories
  • Chronix Biomedical
  • Circulogene
  • Clinical Genomics
  • Cynvenio
  • Cytolumina Technologies Corp.
  • CytoTrack
  • Datar Cancer Genetics Limited
  • Diagnologix LLC
  • Diasorin S.p.A.
  • Enzo Life Sciences, Inc.
  • Epic Sciences
  • Epigenomics AG
  • Eurofins Scientific
  • Exosome Diagnostics
  • Exosome Sciences
  • Fabric Genomics
  • Fluidigm Corp
  • Fluxion Biosciences
  • Foundation Medicine
  • Freenome
  • FUJIFILM Wako Diagnostics
  • GeneFirst Ltd.
  • Genetron Health (Beijing) Co., Ltd.
  • Genomic Health
  • GenomOncology
  • GILUPI Nanomedizin
  • Grail, Inc
  • Guardant Health
  • HalioDx
  • HansaBiomed
  • HeiScreen
  • Helomics
  • Horizon Discovery
  • HTG Molecular Diagnostics
  • iCellate
  • Illumina
  • Incell Dx
  • Inivata
  • Integrated Diagnostics
  • Invivogen
  • Invivoscribe
  • Janssen Diagnostics
  • MDNA Life SCIENCES, Inc
  • MDx Health
  • Menarini Silicon Biosystems
  • Millipore Sigma
  • Miltenyi Biotec
  • MIODx
  • miR Scientific
  • Molecular MD
  • MyCartis
  • Myriad Genetics/Myriad RBM
  • NantHealth, Inc.
  • Natera
  • NeoGenomics
  • New Oncology
  • Novogene Bioinformatics Technology Co., Ltd.
  • Oncocyte
  • OncoDNA
  • Ortho Clinical Diagnostics
  • Oxford Nanopore Technologies
  • Panagene
  • Perkin Elmer
  • Personal Genome Diagnostics
  • Personalis
  • Precipio
  • PrecisionMed
  • Promega
  • Qiagen Gmbh
  • Rarecells SAS
  • RareCyte
  • Roche Molecular Diagnostics
  • Screencell
  • Sense Biodetection.
  • Serametrix
  • Siemens Healthineers
  • Silicon Biosystems
  • simfo GmbH
  • Singlera Genomics Inc
  • Singulomics
  • SkylineDx
  • Stratos Genomics
  • Sysmex Inostics
  • Tempus Labs, Inc.
  • Thermo Fisher Scientific Inc
  • Thrive Earlier Detection
  • Todos Medical
  • Trovagene
  • Volition
  • Vortex Biosciences

第9章 世界のがん分子診断 (MDx) 市場

  • がん分子診断 (MDx) - 世界市場の概要:国別
  • 世界市場:がんの種類別 - 概要
  • 世界市場:製品タイプ別 - 概要
  • 世界市場 :場所別 - 概要

第10章 世界のがん分子診断 (MDx) 市場:がんの種類別

  • 乳がん
  • 大腸がん
  • 子宮頸がん
  • 肺がん
  • 前立腺
  • 黒色腫
  • 血液
  • コンパニオン診断
  • その他のがん

第11章 世界市場:製品タイプ別

  • 計器
  • 試薬
  • ソフトウェア・サービス

第12章 世界市場:場所別

  • 臨床検査室
  • 製薬
  • 研究

第13章 がん治療と治験

  • FDAの抗がん剤承認:年別
  • 治験の開始
  • がん治療の有病率

第14章 付録

図表

Table of Tables

  • Table 1 Lab Spending 2014 to 2024
  • Table 2 Market Players by Type
  • Table 3 Clinical Laboratory Departments and Segments
  • Table 4 Laboratory Management Focus - Different Approaches
  • Table 5 Key Segmentation Variables Going Forward
  • Table 6 Five Factors Driving Growth
  • Table 7 Four Factors Limiting Growth
  • Table 8 Key Diagnostic Laboratory Technology Trends
  • Table 9 Next Generation Sequencing Technologies - Speed and Cost
  • Table 10 - Global MDx Cancer Market by Region
  • Table 11 Global Market by Cancer Type
  • Table 12 Global Market by Product Type
  • Table 13 Global Market by Place
  • Table 14 MDx Breast Cancer by Country
  • Table 15 MDx Colorectal Cancer by Country
  • Table 16 Cervical Cancer Testing by Country
  • Table 17 Lung Cancer Testing by Country
  • Table 18 Prostate Testing by Country
  • Table 19 Melanoma Cancer Testing by Country
  • Table 20 MDx Blood by Country
  • Table 21 MDx Companion Dx Development by Country
  • Table 22 MDx Other Cancer Testing by Country
  • Table 23 MDx Instruments by Country
  • Table 24 MDx Reagents by Country
  • Table 25 Software and Services by Country
  • Table 26 MDx Clinical Laboratory by Country
  • Table 27 MDx Pharmaceutical by Country
  • Table 28 Research by Country
  • Table 29 2021 Clinical Lab Fee Schedule

Table of Figures

  • Figure 1 Clinical Lab Spending 2014 to 2024
  • Figure 2 Growth in Aging Population
  • Figure 3 Death Rates from Cancer - USA
  • Figure 4 Comparing MDx Diagnostic and Traditional Testing
  • Figure 5 Global Market Shares Base Year
  • Figure 6 MDx Market by Cancer - Base vs. Final
  • Figure 7 Cancer Market Base Year
  • Figure 8 Cancer Market Final Year
  • Figure 9 MDx Cancer Share by Year
  • Figure 10 MDx Cancer Segment Growth Rates
  • Figure 11 MDx Market by Product - Base vs. Final
  • Figure 12 Product Market Base Year
  • Figure 13 Product Market Final Year
  • Figure 14 MDx Product Share by Year
  • Figure 15 MDx Product Segment Growth Rates
  • Figure 16 MDx Market by Place - Base vs. Final
  • Figure 17 Place Market Base Year
  • Figure 18 Place Market Final Year
  • Figure 19 MDx Place Share by Year
  • Figure 20 MDx Place Segment Growth Rates
  • Figure 21 Breast Cancer Testing Growth
  • Figure 22 Colorectal Cancer Testing Growth
  • Figure 23 Cervical Cancer Testing Growth
  • Figure 24 Lung Cancer Testing Growth
  • Figure 25 Prostate Testing Growth
  • Figure 26 Melanoma Cancer Testing Growth
  • Figure 27 Blood Testing Growth
  • Figure 28 Companion Dx Development Growth
  • Figure 29 Other Cancer Testing Growth
  • Figure 30 Instruments Growth
  • Figure 31 Reagents Growth
  • Figure 32 Software and Services Growth
  • Figure 33 Clinical Laboratory Growth
  • Figure 34 Pharmaceutical Growth
  • Figure 35 Research Growth
  • Figure 36 FDA Cancer Drug Approvals by Year
  • Figure 37 Clinical Trials for Immunotherapy by Year
  • Figure 38 Pie Chart of Prevalence of Cancer Treatments
目次

OVERVIEW:

A market with fundamental growth factors is impacted by the COVID-19 Pandemic. Molecular Diagnostics for Cancer is positioned to directly benefit from the explosion in genomics knowledge but shifting resources to deal with the COVID emergency may interrupt growth. Learn all about it in this new report from Howe Sound Research. We include a special segment Cancer Companion Diagnostics, a new segment of the market that is reshaping the industry. And now over 130 companies are profiled. A range of dynamic trends are pushing market growth and company valuations. Trends like ......

  • personalized medicine
  • pharmacogenomics
  • liquid biopsy
  • emergence of new economies with large markets
  • greater understanding of the role of genetic material in Disease and Health

Working against this dynamic market are the forces of the COVID Driven Recession. Our latest numbers factor in the different COVID forces and their timing. And their effect on growth.

Exciting technical developments especially in the area of pharmacogenics hold the promise of a dynamic, growing and evolving world market that is moving out of the national and regional orientation and onto a global stage.

In addition customization work, breakouts for particular segments, assistance and support is included free of charge with every report.

Assistance in providing specific growth and market size estimates for new technology tests is normally provided without additional charges. Existing laboratories and hospitals can use the information directly to forecast and plan for clinical facilities growth. Again, assistance in using the information is normally provided without additional charges.

The report includes detailed breakouts for 18 Countries and 4 Regions. A detailed breakout for any country in the world is available to purchasers of the report.

ABOUT THE LEAD AUTHOR:

Mr. Greg Powell, B.SC., M.B.A is the President of Howe Sound Research. He is an experienced business and clinical professional. He is co-author of the paper "The Radioimmunoassay of Angiotensinogen by Antibody Trapping." He has worked in laboratory testing and management for over 20 years. Mr. Powell's education includes:

  • B.Sc. (Chemistry) University of BC
  • M.B.A. (Finance and Policy) University of BC
  • Market Research Seminar - Burke Institute
  • Finance for Senior Executives - Harvard Business School

Table of Contents

1 Molecular Dx Oncology Market - Strategic Situation Analysis with Impact of the COVID Pandemic

2 Guide for Executives, Marketing, Sales and Business Development Staff

3 Guide for Management Consultants and Investment Advisors

4 Introduction and Market Definition

  • 4.1 What is Molecular Diagnostics
  • 4.2 The Diagnostics Revolution
  • 4.3 Market Definition
    • 4.3.1 Revenue Market Size
  • 4.4 Methodology
    • 4.4.1 Authors
    • 4.4.2 Sources
  • 4.5 U.S. Medical Market and laboratory Testing - Perspective
    • 4.5.1 U.S. Medicare Expenditures for Laboratory Testing

5 Market Overview

  • 5.1 Market Participants
    • 5.1.1 Academic Research Lab
    • 5.1.2 Diagnostic Test Developer
    • 5.1.3 Genomic Instrumentation Supplier
    • 5.1.4 Cell Separation and Viewing Instrumentation Supplier.
    • 5.1.5 Pharmaceutical/Reagent Supplier
    • 5.1.6 Independent Testing Lab
    • 5.1.7 Public National/regional lab
    • 5.1.8 Hospital lab
    • 5.1.9 Physician Lab
    • 5.1.10 Audit Bodies
    • 5.1.11 Certification Body
  • 5.2 Market Segments
    • 5.2.1 Traditional Market Segmentation
    • 5.2.2 Laboratory Focus and Segmentation
  • 5.3 Industry Structure
    • 5.3.1 Hospital Testing Share
    • 5.3.2 Economies of Scale
    • 5.3.3 Physician Office Lab's
    • 5.3.4 Physician's and POCT

6 Market Trends

  • 6.1 Factors Driving Growth
    • 6.1.1 New Diagnostics Create New Markets
    • 6.1.2 New Roles for Diagnostics
    • 6.1.3 Longevity and Outcomes
    • 6.1.4 Expanding the Pharmaceutical Toolbox
    • 6.1.5 Regulatory Retreat
  • 6.2 Factors Limiting Growth
    • 6.2.1 Falling Prices
    • 6.2.2 Lower Costs
    • 6.2.3 COVID Pandemic
    • 6.2.4 Wellness has a Downside
  • 6.3 Instrumentation and Automation
    • 6.3.1 Instruments Key to Market Share
    • 6.3.2 Bioinformatics Plays a Role
  • 6.4 Diagnostic Technology Development
    • 6.4.1 Next Generation Sequencing
    • 6.4.2 Shifting Role of Diagnostics
    • 6.4.3 Multiplexing and Foundation One
    • 6.4.4 Pharmacogenomics Technology
    • 6.4.5 Whole Genome Sequencing
    • 6.4.6 Gene Editing and Gene Therapy

7 Molecular Diagnostics Recent Developments

  • 7.1 Recent Developments - Importance and How to Use This Section
    • 7.1.1 Importance of These Developments
    • 7.1.2 How to Use This Section
  • 7.2 Nucleix to Invest in Early-Stage Lung Cancer Dx
  • 7.3 Invitae to Acquire Genosity for $200M
  • 7.4 Bio-Techne Obtains CE Mark for Exosomal Liquid Biopsy Prostate Test
  • 7.5 Agilent Technologies to Acquire Liquid Biopsy Firm Resolution Bioscience
  • 7.6 Natera Revenues Grow 35 Percent
  • 7.7 AnchorDx Closes $40M Financing Round
  • 7.8 Exact Sciences Strategy for End-to-End Cancer Testing
  • 7.9 Genomics England: Whole Genome Sequencing for Cancer Patients to Launch
  • 7.10 Singlera Genomics Closes $150M Funding for Cancer Screening
  • 7.11 Biocartis GeneproDx, Endpoint Health Collaborate on Tests for Idylla Platform
  • 7.12 Wales to Routinely Screen Cancer Patients With Yourgene Elucigene Test
  • 7.13 Metastatic Cancer Markers Identified in Clinical WGS Study
  • 7.14 Stitch Bio Bets on CRISPR Tech
  • 7.15 Bayer, LifeLabs Launch Free NTRK Genetic Testing Program
  • 7.16 Foundation Medicine Liquid Biopsy Gets FDA Approval for Multiple Companion Dx
  • 7.17 Progress, Challenges in Liquid Biopsy Reimbursement
  • 7.18 Israeli Startup Curesponse Raises $6M
  • 7.19 Coronavirus Pandemic Bites into European Cancer Research
  • 7.20 Veracyte's Prosigna IDs Patients Likely to Benefit from Aggressive Chemotherapy
  • 7.21 Combining CRISPR and Nanopore Sequencing
  • 7.22 Liquid Biopsy Detects Cancer Early via Cell Clusters
  • 7.23 Roche, Illumina unveil 15-year cancer diagnostic tie-up
  • 7.24 Saga, Servier Sign Liquid Biopsy Services Deal
  • 7.25 Home urine test could revolutionize diagnosis of prostate cancer
  • 7.26 Cancer Gene Tests Cost-Effective for Breast Cancer Patients
  • 7.27 Personal Genome Diagnostics Gets CE Mark for Elio Tissue Assay
  • 7.28 OncoCyte to Buy Cancer Testing Company Razor Genomics
  • 7.29 Blood Test May Eliminate Need for Exploratory Surgery
  • 7.30 NGS Cancer Panel Receives New York State Conditional Approval
  • 7.31 Biocartis Inks Cancer CDx Deal With Bristol-Myers Squibb

8 Profiles of Key MDx Companies

  • 8.1 10x Genomics, Inc
  • 8.2 Abbott Diagnostics
  • 8.3 AccuraGen Inc.
  • 8.4 Adaptive Biotechnologies
  • 8.5 Aethlon Medical
  • 8.6 Agena Bioscience, Inc.
  • 8.7 Agilent
  • 8.8 Anchor Dx
  • 8.9 ANGLE plc
  • 8.10 ApoCell, Inc.
  • 8.11 ArcherDx, Inc.
  • 8.12 ARUP Laboratories
  • 8.13 Asuragen
  • 8.14 AVIVA Biosciences
  • 8.15 Baylor Miraca Genetics Laboratories
  • 8.16 Beckman Coulter, Inc.
  • 8.17 BGI Genomics Co. Ltd
  • 8.18 Bioarray Genetics
  • 8.19 Biocartis
  • 8.20 Biocept, Inc
  • 8.21 Biodesix Inc.
  • 8.22 BioFluidica
  • 8.23 BioGenex
  • 8.24 Biolidics Ltd
  • 8.25 bioMérieux Diagnostics
  • 8.26 Bioneer Corporation
  • 8.27 Bio-Rad Laboratories, Inc
  • 8.28 Bio-Reference Laboratories
  • 8.29 Bio-Techne
  • 8.30 Bioview
  • 8.31 Bolidics
  • 8.32 Boreal Genomics
  • 8.33 Bristol-Myers Squibb
  • 8.34 Cancer Genetics
  • 8.35 Caris Molecular Diagnostics
  • 8.36 CellMax Life
  • 8.37 Cepheid (now Danaher)
  • 8.38 Charles River Laboratories
  • 8.39 Chronix Biomedical
  • 8.40 Circulogene
  • 8.41 Clinical Genomics
  • 8.42 Cynvenio
  • 8.43 Cytolumina Technologies Corp.
  • 8.44 CytoTrack
  • 8.45 Datar Cancer Genetics Limited
  • 8.46 Diagnologix LLC
  • 8.47 Diasorin S.p.A.
  • 8.48 Enzo Life Sciences, Inc.
  • 8.49 Epic Sciences
  • 8.50 Epigenomics AG
  • 8.51 Eurofins Scientific
  • 8.52 Exosome Diagnostics
  • 8.53 Exosome Sciences
  • 8.54 Fabric Genomics
  • 8.55 Fluidigm Corp
  • 8.56 Fluxion Biosciences
  • 8.57 Foundation Medicine
  • 8.58 Freenome
  • 8.59 FUJIFILM Wako Diagnostics
  • 8.60 GeneFirst Ltd.
  • 8.61 Genetron Health (Beijing) Co., Ltd.
  • 8.62 Genomic Health
  • 8.63 GenomOncology
  • 8.64 GILUPI Nanomedizin
  • 8.65 Grail, Inc
  • 8.66 Guardant Health
  • 8.67 HalioDx
  • 8.68 HansaBiomed
  • 8.69 HeiScreen
  • 8.70 Helomics
  • 8.71 Horizon Discovery
  • 8.72 HTG Molecular Diagnostics
  • 8.73 iCellate
  • 8.74 Illumina
  • 8.75 Incell Dx
  • 8.76 Inivata
  • 8.77 Integrated Diagnostics
  • 8.78 Invivogen
  • 8.79 Invivoscribe
  • 8.80 Janssen Diagnostics
  • 8.81 MDNA Life SCIENCES, Inc
  • 8.82 MDx Health
  • 8.83 Menarini Silicon Biosystems
  • 8.84 Millipore Sigma
  • 8.85 Miltenyi Biotec
  • 8.86 MIODx
  • 8.87 miR Scientific
  • 8.88 Molecular MD
  • 8.89 MyCartis
  • 8.90 Myriad Genetics/Myriad RBM
  • 8.91 NantHealth, Inc.
  • 8.92 Natera
  • 8.93 NeoGenomics
  • 8.94 New Oncology
  • 8.95 Novogene Bioinformatics Technology Co., Ltd.
  • 8.96 Oncocyte
  • 8.97 OncoDNA
  • 8.98 Ortho Clinical Diagnostics
  • 8.99 Oxford Nanopore Technologies
  • 8.100 Panagene
  • 8.101 Perkin Elmer
  • 8.102 Personal Genome Diagnostics
  • 8.103 Personalis
  • 8.104 Precipio
  • 8.105 PrecisionMed
  • 8.106 Promega
  • 8.107 Qiagen Gmbh
  • 8.108 Rarecells SAS
  • 8.109 RareCyte
  • 8.110 Roche Molecular Diagnostics
  • 8.111 Screencell
  • 8.112 Sense Biodetection.
  • 8.113 Serametrix
  • 8.114 Siemens Healthineers
  • 8.115 Silicon Biosystems
  • 8.116 simfo GmbH
  • 8.117 Singlera Genomics Inc
  • 8.118 Singulomics
  • 8.119 SkylineDx
  • 8.120 Stratos Genomics
  • 8.121 Sysmex Inostics
  • 8.122 Tempus Labs, Inc.
  • 8.123 Thermo Fisher Scientific Inc
  • 8.124 Thrive Earlier Detection
  • 8.125 Todos Medical
  • 8.126 Trovagene
  • 8.127 Volition
  • 8.128 Vortex Biosciences

9 The Global Market for MDx Cancer

  • 9.1 MDx Cancer - Global Market Overview by Country
    • 9.1.1 Table - Global Market by Country
    • 9.1.2 Chart - Global Market by Country
  • 9.2 Global Market by Cancer Type - Overview
    • 9.2.1 Table - Global Market by Cancer Type
    • 9.2.2 Chart - Global Market by Cancer Type - Base/Final Comparison
    • 9.2.3 Chart - Global Market by Cancer Type - Base Year
    • 9.2.4 Chart - Global Market by Cancer Type -Final Year
    • 9.2.5 Chart - Global Market by Cancer Type - Share by Year
    • 9.2.6 Chart - Global Market by Cancer Type - Segment Growth
  • 9.3 Global Market by Product Type - Overview
    • 9.3.1 Table - Global Market by Product Type
    • 9.3.2 Chart - Global Market by Product Type - Base/Final Comparison
    • 9.3.3 Chart - Global Market by Product Type - Base Year
    • 9.3.4 Chart - Global Market by Product Type -Final Year
    • 9.3.5 Chart - Global Market by Product Type - Share by Year
    • 9.3.6 Chart - Global Market by Product Type - Segment Growth
  • 9.4 Global Market by Place - Overview
    • 9.4.1 Table - Global Market by Place
    • 9.4.2 Chart - Global Market by Place - Base/Final Comparison
    • 9.4.3 Chart - Global Market by Place - Base Year
    • 9.4.4 Chart - Global Market by Place -Final Year
    • 9.4.5 Chart - Global Market by Place - Share by Year
    • 9.4.6 Chart - Global Market by Place - Segment Growth

10 Global Market by Cancer Type

  • 10.1 MDx Breast Cancer
    • 10.1.1 Table Breast Cancer Testing - by Country
    • 10.1.2 Chart - Breast Cancer Testing Growth
  • 10.2 MDx Colorectal Cancer
    • 10.2.1 Table Colorectal Cancer Testing - by Country
    • 10.2.2 Chart - Colorectal Cancer Testing Growth
  • 10.3 MDx Cervical Cancer
    • 10.3.1 Table Cervical Cancer Testing - by Country
    • 10.3.2 Chart - Cervical Cancer Testing Growth
  • 10.4 MDx Lung Cancer
    • 10.4.1 Table Lung Cancer Testing - by Country
    • 10.4.2 Chart - Lung Cancer Testing Growth
  • 10.5 MDx Prostate
    • 10.5.1 Table Prostate Testing - by Country
    • 10.5.2 Chart - Prostate Testing Growth
  • 10.6 MDx Melanoma Cancer
    • 10.6.1 Table Melanoma Cancer Testing - by Country
    • 10.6.2 Chart - Melanoma Cancer Testing Growth
  • 10.7 MDx Blood
    • 10.7.1 Table Blood Testing - by Country
    • 10.7.2 Chart - Blood Testing Growth
  • 10.8 MDx Companion Dx Development
    • 10.8.1 Table Companion Dx Development - by Country
    • 10.8.2 Chart - Companion Dx Development Growth
  • 10.9 MDx Other Cancer
    • 10.9.1 Table Other Cancer Testing - by Country
    • 10.9.2 Chart - Other Cancer Testing Growth

11 Global Market by Product Type

  • 11.1 MDx Instruments
    • 11.1.1 Table Instruments - by Country
    • 11.1.2 Chart - Instruments Growth
  • 11.2 MDx Reagents
    • 11.2.1 Table Reagents - by Country
    • 11.2.2 Chart - Reagents Growth
  • 11.3 MDx Software and Services
    • 11.3.1 Table Software and Services - by Country
    • 11.3.2 Chart - Software and Services Growth

12 Global Market by Place

  • 12.1 MDx Clinical Laboratory
    • 12.1.1 Table Clinical Laboratory - by Country
    • 12.1.2 Chart - Clinical Laboratory Growth
  • 12.2 MDx Pharmaceutical
    • 12.2.1 Table Pharmaceutical - by Country
    • 12.2.2 Chart - Pharmaceutical Growth
  • 12.3 MDx Research
    • 12.3.1 Table Research - by Country
    • 12.3.2 Chart - Research Growth

13 Cancer Treatment and Trials

  • 13.1 FDA Cancer Drug Approvals by Year
  • 13.2 Clinical Trials Started 2010 to 2016
  • 13.3 Prevalence of Cancer Treatments - 2015

14 Appendices

  • 14.1 United States Medicare System: January 2021 Clinical Laboratory Fees Schedule
  • 14.2 FDA Approved Human Genetic Tests
  • 14.3 FDA Approved Microbial Tests
  • 14.4 FDA Approved Pharmacogenomics Tests
株式会社グローバルインフォメーション
© Copyright 1996-2021, Global Information, Inc. All rights reserved.